v3.26.1
Acquisitions and Divestiture (Tables)
 6 Months Ended
Jun. 27, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Schedule of Components of Purchase Price and Net Assets Acquired
The components of the preliminary purchase price and net assets acquired are as follows:
(In millions)Clario
Purchase price
Cash paid
$5,806 
Debt settled3,180 
Purchase price payable121 
Fair value of contingent consideration
108 
Cash acquired
(117)
$9,098 
Net assets acquired
Definite-lived intangible assets
Customer relationships
$2,510 
Product technology
844 
Trade names
19 
Backlog
423 
Goodwill
5,934 
Net other assets/(liabilities)
386 
Contract liabilities
(375)
Deferred tax assets/(liabilities)
(645)
$9,098 
On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, our filtration and separation business, a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications, from Solventum Corporation. The business strengthens the segment’s bioproduction offerings with advanced filtration technologies that improve quality and efficiency across upstream and downstream workflows. In addition, its industrial filtration and membrane solutions will expand our reach into industries including battery, semiconductor and medical device manufacturing. The goodwill recorded as a result of this business combination is not tax deductible.
The components of the preliminary purchase price and net assets acquired are as follows:
(In millions)Filtration and separation business
Purchase price
Cash paid
$3,939 
Fair value of contingent consideration
(66)
Cash acquired
(9)
$3,865 
Net assets acquired
Property, plant and equipment
$469 
Definite-lived intangible assets
Customer relationships
1,116 
Product technology
388 
Trade names
51 
Goodwill
2,065 
Net other assets/(liabilities)
152 
Deferred tax assets/(liabilities)
(376)
$3,865 
Disposal Groups, Including Discontinued Operations The assets and liabilities of the microbiology business were as follows as of June 27, 2026:
(In millions)
Current assets$228 
Long-term assets760 
Current liabilities71 
Long-term liabilities45